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Background: Hallucinations are prevalent in schizophrenia and related psychotic disorders and may have severe
consequences for the affected patients. Antipsychotic drug trials that specifically address the anti-hallucinatory
effectiveness of the respective drugs in representative samples are rare. The aims of the present study were to
investigate the rate and severity of hallucinations in acutely admitted psychotic patients at hospital admission and
discharge or after 6 weeks at the latest, if not discharged earlier (discharge/6 weeks); and to compare the
anti-hallucinatory effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone with up to 2 years’ follow-up.
Methods: Adult patients acutely admitted to an emergency ward for psychosis were consecutively randomized to
risperidone, olanzapine, quetiapine, or ziprasidone and followed for up to 2 years in a pragmatic design. Participants
were assessed repeatedly using the hallucinatory behavior item of the Positive and Negative Syndrome Scale (PANSS).
Results: A total of 226 patients, 30.5% of those assessed for eligibility, were randomized and 68% were hallucinating at
baseline. This proportion was reduced to 33% at discharge/6 weeks. In the primary analyses based on intention to treat
groups of patients experiencing frequent hallucinations, the quetiapine and ziprasidone groups both had faster
decreases of the mean hallucination scores than the risperidone group.
Conclusions: Hallucinations are fairly responsive to antipsychotic drug treatment and differential anti-hallucinatory
effectiveness may be found among existing antipsychotic drugs. If replicated, this could pave the way for a more
targeted pharmacotherapy based on individual symptom profiles, rather than on the diagnostic category.
Trial registration: ClinicalTrials.gov ID; NCT00932529Background
Hallucinations, most often auditory in nature, are highly
prevalent in schizophrenia and related psychotic disorders
but prevalence figures vary greatly among different reports
[1]. Auditory hallucinations in schizophrenia can be dra-
matic and may have severe impact in affected individuals,
and are sometimes associated with suicidality [2-4], vio-
lence [5,6], and homicide [7]. Accordingly, hallucinations* Correspondence: erij@helse-bergen.no
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reproduction in any medium, provided the orhave traditionally been one of the main treatment targets
for antipsychotic drugs and indeed the positive psychotic
symptoms of schizophrenia collectively are far more re-
sponsive to these drugs than negative or other cognitive
symptoms [8,9]. Importantly, patients with schizophrenia
and related disorders are a very heterogeneous group
symptomatically [10]. Consequently, to optimize treatment
effectiveness in different symptomatic subgroups of pa-
tients, individually tailoring drug regimens should be an
important aim. However, the results from clinical drug tri-
als very rarely focus on single symptom scores such as hal-
lucinations but typically report group mean changes of
overall psychopathology, or at best the positive subscalel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Scale (PANSS) [11] the hallucination item is one of a total
of 7 items in the positive subscale which also includes
Delusions, Conceptual disorganization, Excitement, Gran-
diosity, Suspiciousness, and Hostility. There is an obvious
risk that differential anti-hallucinatory effectiveness among
antipsychotic drugs may be obscured by means of sum
scores for the whole sample in clinical trials.
We have previously reported differential effectiveness for
risperidone, olanzapine, quetiapine, and ziprasidone for
overall change of the PANSS total and positive subscale
scores, respectively [12]. The present study focuses on hal-
lucinations and the hallucinatory behavior (hallucinations)
item in the PANSS. The aims of the study were to investi-
gate the rate and severity of hallucinations at hospital
admission and discharge, or at 6 weeks from baseline at
the latest, if not discharged earlier (discharge/6 weeks),
in a large sample of patients acutely admitted with psych-
osis. Moreover, the study aimed to compare the anti-
hallucinatory effectiveness of the second generation anti-
psychotic drugs (SGAs) risperidone, olanzapine, quetiapine,
and ziprasidone with up to 2 years’ follow-up.
Methods
Study design
The methods used in this study have been described in
more detail in a previous publication [12]. The project
was a 2-year, prospective, rater-blind, pragmatic, random-
ized, head-to-head comparison of risperidone, olanzapine,
quetiapine, and ziprasidone conducted at Haukeland Uni-
versity Hospital, Bergen, Norway (see Figure 1 for the pa-
tient flow in the project).
The project was approved by the Regional Committee
for Medical Research Ethics and the Norwegian Social
Science Data Services, was publicly funded and did not
receive any financial or other support from the pharma-
ceutical industry.
Patients
The Regional Committee for Medical Research Ethics
allowed eligible patients to be included before informed
consent was provided, thus entailing a clinically relevant
representation in the study.
Inclusion criteria
Adult patients were eligible for the study if they were ad-
mitted to the emergency ward for symptoms of active
psychosis as determined by a score of ≥ 4 on one or more
of the items Delusions, Hallucinatory behavior, Grandios-
ity, Suspiciousness/persecution, or Unusual thought con-
tent in the PANSS [11], and were candidates for oral
antipsychotic drug therapy with one of the study drugs.
Importantly, the study drugs represented the available
first-choice SGAs in Norway for psychosis at the time ofthe conductance of the study. All eligible patients met
the ICD-10 (http://apps.who.int/classifications/icd10/browse/
2010/en) diagnostic criteria for schizophrenia, schizoaffective
disorder, acute and transient psychotic disorder, delusional
disorder, drug-induced psychosis, bipolar disorder except
manic psychosis, or major depressive disorder with psychotic
features. The diagnoses were determined by the hospital’s
psychiatrists or specialists in clinical psychology.
Exclusion criteria
Patients were excluded from the study if they were unable to
use oral antipsychotics, were suffering from manic psychosis
or for other behavioral or mental reasons related to the state
of illness were unable to cooperate with assessments, did not
understand spoken Norwegian, were candidates for electro-
convulsive therapy, or were medicated with clozapine on
admittance. Patients with drug-induced psychoses were in-
cluded only when the condition did not resolve within a few
days and when antipsychotic drug therapy was indicated.
Treatments
At admission, a sealed and numbered envelope was opened
by the treating psychiatrist or physician and then the pa-
tient was offered the first drug in a random sequence of
risperidone, olanzapine, quetiapine, or ziprasidone. The
randomization was open to the treating psychiatrist or
physician and to the patient, and either party could discard
the SGA listed as #1 on the list because of medical contra-
indications for the use of, or prior negative experiences
with the drug, and the next drug on the list could be
chosen. The same principle was followed if the next drug
could not be used. The protocol thus mimicked the usual
clinical situation in which oral antipsychotic drug therapy
is initiated: To prospectively predict which antipsychotic
might be optimal for a given patient is not possible based
on the current evidence [13], but a prior history of anti-
psychotic drug use may provide useful information for de-
cision making. A reason for discarding drugs should be
explicitly stated by the treating psychiatrist or physician.
The SGA listed as #1 defined the randomization group
(RG) which is the basis of the primary analysis. The actual
SGA chosen, regardless of randomization group, defined
the first-choice group (FCG). Further dosage, combinations
with other drugs, or switching to another antipsychotic
drug were then left at the treating clinician’s discretion.
Apart from sporadic use, the patients in the project could
use only one antipsychotic drug except during the cross-
titration period during a change in antipsychotic drug
treatment.
Clinical assessments
Study visits by the patients were at baseline, at discharge
or at 6 weeks from baseline at the latest if not discharged
earlier (discharge/6 weeks), and at 3, 6, 12, and 24 months
Randomized
(N=226) (30.5%)
Assessed for eligibility
(100%)1
Excluded
Not meeting inclusion criteria (1.2%)1
Unable to assess 
(uncooperative, organic brain dis.) (46.5%)1
Randomization not acceptable (6.8%)1
Administrative causes (15.0%)1
Risperidone
Allocated to drug (N=57)
Received allocated drug (N=44)
Chose another drug (N=12)
Unknown choice of drug (N=1)
Did not take any drug doses of 
received allocated drug (N=5)
Lost to follow-up2
Uncooperative (N=13)
Polypharmacy (N=4)
Discharge (N=8)
Depot (N=0)
Other (N=1)
Total (N=26)
Follow-up
Discharge/ 6 weeks (N=30)3
3 months (N=15)
6 months (N=10)
12 months (N=11)
24 months (N=3)
Lost to follow-up2
Uncooperative (N=7)
Polypharmacy (N=6)
Discharge (N=15)
Depot (N=1)
Other (N=1)
Total (N=30)
Lost to follow-up2
Uncooperative (N=6)
Polypharmacy (N=1)
Discharge (N=17)
Depot (N=0)
Other (N=1)
Total (N=25)
Follow-up
Discharge/ 6 weeks (N=23)3
3 months (N=14)
6 months (N=11)
12 months (N=9)
24 months (N=6)
Follow-up
Discharge/ 6 weeks (N=27)
3 months (N=11)
6 months (N=8)
12 months (N=6)
24 months (N=5)
Follow-up
Discharge/ 6 weeks (N=29) 
3 months (N=12)
6 months (N=9)
12 months (N=7)
24 months (N=1)
Analyzed (N=57) Analyzed (N=54) Analyzed (N=52) Analyzed (N=63)
Lost to follow-up2
Uncooperative (N=7)
Polypharmacy (N=6)
Discharge (N=12)
Depot (N=1)
Other (N=8)
Total (N=34)
Olanzapine
Allocated to drug (N=54)
Received allocated drug (N=45)
Chose another drug (N=9)
Did not take any drug doses of 
received allocated drug (N=5)
Quetiapine
Allocated to drug (N=52)
Received allocated drug (44)
Chose another drug (N=8)
Did not take any drug doses of 
received allocated drug (N=3)
Ziprasidone
Allocated to drug (N=63)
Received allocated drug (=52)
Chose another drug (N=11)
Did not take any drug doses of 
received allocated drug (N=4)
Figure 1 Flow of patients through the study. Not meeting inclusion criteria = a score below 4 on all items: Delusions, Hallucinatory Behavior,
Grandiosity, Suspiciousness/Persecution, or Unusual thought content in the Positive and Negative Syndrome Scale (PANSS); Uncooperative = the
patient was not able or willing to cooperate with testing and assessments; Organic brain dis. = Organic brain disorder, principally dementia;
Randomization not acceptable = patient or treating clinician not willing to change existing antipsychotic medication; Administrative causes =
principally the result of patient discharge before assessments could be made.1 Enrollment started in 2003, week 10 until 2008, week 26. Full
details on enrollment were only registered from 2006, week 31 until 2008, week 26. Consequently only percentages are displayed for patients
assessed for eligibility and excluded patients.2 Before discharge/6 weeks. 3 One patient in the risperidone and olanzapine groups missed the first
follow-up visit, but was retested on later visits.
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changed their antipsychotic medication during the inclu-
sion period, but importantly only data obtained during the
use of the first antipsychotic drug have been included in
the present study.Baseline
Before inclusion, eligible patients underwent the PANSS
structured clinical interview. Intra-class correlation coef-
ficients (ICC) were calculated based on inter-rater as-
sessments and showed high inter-rater reliability (0.92).
Furthermore, the patients underwent assessments using
the Calgary Depression Scale for Schizophrenia (CDSS)
[14], and the Clinical Drug and Alcohol Use Scales
(CDUS/CAUS) [15], as well as a neurocognitive test bat-
tery, and were rated according to the Clinical GlobalImpression—Severity of Illness scale (CGI-S) [16], and
the Global Assessment of Functioning—Split Version,
Functions scale (GAF-F) [17].Discharge/ 6 weeks
At discharge/6 weeks, the tests and examinations were
repeated by raters unaware of which treatment the pa-
tient was receiving. Serum level concentration of the
antipsychotic drug was measured. All of these tests
and measurements were part of the hospital’s routine
procedure for the handling and management of pa-
tients suffering from psychosis, and was included in
the patient’s medical record. At this point in the study
procedure, the patients were asked for written in-
formed consent to be later contacted and asked to par-
ticipate in the follow-up project.
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At follow-up visits 3, 6, 12, and 24 months after baseline
the same measures and tests were repeated, and all medi-
cation use was recorded. Doses for the accepted sporadic
use of antipsychotics other than the SGAs under investiga-
tion were converted to chlorpromazine equivalent doses
[18]. In cases where chlorpromazine equivalent doses
could not be found in the literature, this was done by con-
version to defined daily doses (DDDs) as developed by the
World Health Organization Collaborating Center for Drug
Statistics Methodology (http://www.whocc.no/atcddd/).Statistical procedures
Categorical and continuous data at baseline and at dis-
charge/6 weeks, respectively, were analyzed by means of
exact χ2 - tests and one-way ANOVAs by using the SPSS
software, version 20.0 (IBM SPSS Statistics, 2011). For
comparing mean hallucination scores at baseline and at
discharge/6 weeks, paired-sample t-tests were used. For
baseline comparisons between the patients lost to follow-
up before retesting and the patients who were retested,
independent-sample t-tests were used for continuous data
and exact χ2 - tests for categorical data. Comparisons of
the time until discontinuation of the individual drug were
analyzed by means of Kaplan-Meier survival analyses. Pa-
tients with a score of 3 or more on the hallucinations item
in the PANSS, hereafter termed the Hallucinatory Patients
(HP) subgroup, were followed longitudinally over the
measurement period of up to 2 years. The primary ana-
lyses were intention-to-treat (ITT) analyses based on the
randomization groups (RGs); that is, trial participants
were analyzed in the group to which they were random-
ized regardless of which antipsychotic treatment they
actually received. This is in accordance with the recom-
mendations of the Cochrane Handbook for Systematic Re-
views of Interventions [19]. The analyses based on the
actual SGA chosen at baseline, the first-choice groups
(FCGs), were considered secondary analyses as these
groups were not based on randomization but rather on
the active choice of the patient or treating psychiatrist/
physician. Change of the PANSS hallucinations item score
was analyzed in R by means of a linear mixed-effects
(LME) model (http://www.r-project.org) [20]. Fixed ef-
fects, i.e. systematic differences between the drugs, gave
different linear slopes in the four treatment groups, tech-
nically a group by time interaction with no baseline group
differences. The model calculated overall change per time
unit for the variables in the follow-up period that could be
visually represented by the slope of a linear curve with
time on the x-axis and the hallucination score on the y-
axis. For multiple comparisons, Benjamini-Hochberg ad-
justments were applied. The level of statistical significance
was set at α = 0.05, two-sided.Power analyses
Power estimations were conducted in R by means of LME
models. The baseline mean hallucinations item score and
standard deviations (SD) were based on the results of the
model used, and slopes corresponding to what was consid-
ered the least clinically significant difference among the
drug groups were entered into the model. An estimated
dropout rate of 3% per month was used and 10,000 simu-
lations were run. The power analyses revealed that with 37
subjects in each treatment arm the trial had 96% power to
detect 12.5% differences in the change of the hallucina-
tions item score among the drug groups, whereas the trial
had 81% power to detect 10% differences. Smaller differ-
ences had inferior power but were not considered clinic-
ally significant.
Results
The total sample
A total of 226 patients, 152 (67.3%) males, were included
and randomized to one of the study drugs (Figure 1). The
mean age was 34.1 years, the standard deviation (SD) 13.5.
About half the sample was antipsychotic drug naïve at in-
clusion meaning no prior exposure to antipsychotic agents,
whereas the rest had a life-time exposure to antipsychotic
drugs. The mean PANSS total score at baseline was 74.0
(13.4), range 44–111, and the global neurocognitive func-
tioning t-score was 38.2 (7.7). A total of 154 (68.1%) pa-
tients had a PANSS hallucinations item (P3) score of 3 or
more at baseline (the Hallucinating Patients (HP) sub-
group); see dispersion of ratings in Figure 2.
The mean and median time periods between baseline
and discharge/6 weeks were 28.5 and 28.0 days, SD 14.2,
respectively. The proportion with hallucinations was 33.0%
at discharge/6 weeks. The reduction of the proportion with
hallucinations was statistically significant (Exact χ2- test:
p = 0.014). The mean hallucinations score was reduced from
3.6 at baseline to 2.0 at discharge/6 weeks (paired-samples
t-test: p < 0.001; mean difference 1.6; 95% CI 1.2-1.9).
The sub-sample with hallucinations
In the HP subgroup that was followed for up to 2 years, the
dispersion of patients among the randomization groups was
37, 37, 38, and 42 for risperidone, olanzapine, quetiapine,
and ziprasidone, respectively. Demographics and clinical
characteristics of the HP subgroup are displayed in Table 1,
with no differences among the groups.
There were no differences between those patients lost to
follow-up before retesting and those who were retested on
clinical and demographic characteristics. A total of 78.4%
of the patients chose the #1 drug on the list. There were
no significant differences between the randomization
groups for the proportion that accepted the #1 drug, nor
was there any difference for the choice of actual drug. The
mean daily doses, with SD, were 3.4 (1.2) mg, 14.8 (5.4)
Figure 2 Dispersion of baseline scores of the PANSS hallucinations item.
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done, olanzapine, quetiapine, and ziprasidone groups, re-
spectively. The mean serum levels in nanomoles per liter
with SD and reference ranges in brackets were 68.5 (56.2)
[30–120], 90.3 (64.4) [30–200], 321.5 (407.3) [100–800],
and 107.2 (73.1) [30–200] for risperidone, olanzapine,
quetiapine, and ziprasidone, respectively. There were no
significant differences between the groups with regards to
the use of concomitant psychotropics such as the sporadic
use of another antipsychotic drug (N = 11); concomitant
antidepressants (N = 19); mood stabilizers (N = 5); benzo-
diazepines (N = 15); or anti-cholinergic drugs (N = 9)
during follow-up. Neither were there any significant differ-
ences between the drugs with regards to the use of anti-
psychotics or type of antipsychotic drugs in the year prior
to inclusion in the study. The mean and median time until
discontinuation of the randomization drugs with standard
error (SE) were 369.6 (72.4) days and 77.0 (26.7) days, re-
spectively, with no significant differences between the
randomization groups.
The primary LME analyses
In the primary LME analyses that were intention-
to-treat analyses based on the randomization groups, the
slopes with standard error (SE) were −0.0007 (0.0013),
−0.0037 (0.0010), −0.0046 (0.0011), and −0.0054 (0.0015)
for risperidone, olanzapine, quetiapine, and ziprasidone,
respectively (Figure 3). The quetiapine and ziprasidone
groups had significantly steeper slopes than the risperi-
done group (LME: p = .027, adjusted for multiple com-
parisons). The distribution of slopes among the groups
remained unaltered in the sensitivity analyses also afteradjusting for numerically more drug-naïve patients in
the quetiapine and ziprasidone groups. The distribution
of slopes for the groups remained unaltered (−0.0020
(0.0018), −0.0036 (0.0011), −0.0047 (0.0011), and −0.0061
((0.0025)) for risperidone, olanzapine, quetiapine, and
ziprasidone, respectively, although the difference did not
reach statistical significance, even when patients that did
not accept the #1 drug on the list were excluded.
The secondary LME analyses
In the secondary analyses based on first-choice groups
there were no significant baseline differences among the
groups with regards to clinical characteristics and demo-
graphics except for a higher mean PANSS positive subscale
score in the olanzapine group (22.5 points) than in the
ziprasidone group (19.8 points) (one-way ANOVA: p =
0.032; mean difference 2.7 points; 95% CI 0.15-5.3). In the
LME analyses there were no significant differences among
the groups.
Discussion
The main findings of the present study are that in a con-
secutive sample of patients acutely admitted to hospital
with symptoms of psychosis more than two-thirds had
hallucinations at admittance whereas only one-third was
hallucinating at discharge/6 weeks. The mean PANSS
hallucination score also declined significantly. A sub-
stantial reduction of frequency and severity of hallucina-
tions can thus be expected in about half the cases during
the first month after hospital admittance. Moreover, dif-
ferential anti-hallucinatory effectiveness was found in
the primary intention-to-treat analyses among the drugs
Table 1 Baseline demographics and clinical characteristics of hallucinations group
Randomization groups
Characteristics Risperidone (N = 37) Olanzapine (N = 37) Quetiapine (N = 38) Ziprasidone (N = 42) All patients (N = 154)
N % N % N % N % N %
Gender
Male 28 75.7 24 64.9 24 63.2 25 59.5 101 65.6
Antipsychotic naïve 13 36.1 14 37.8 21 55.3 22 52.4 70 45.8
Alcohol last 6 months
None 11 29.7 6 16.2 5 13.2 8 19.5 30 19.6
Misuse 3 8.1 4 10.8 9 23.7 4 9.8 20 13.1
Drugs last 6 months
None 19 52.8 26 70.3 28 73.7 26 63.4 99 65.1
Misuse 11 30.6 6 16.2 5 13.1 9 21.9 31 20.4
Diagnosis1
Schz and rel. 18 52.9 16 44.5 24 63.1 20 51.3 78 53.1
Acute 2 5.9 8 22.2 3 7.9 4 10.3 17 11.6
Drug-induced 8 23.5 4 11.1 6 15.8 5 12.8 23 15.6
Affective 3 8.8 4 11.1 3 7.9 3 7.7 13 8.8
Rest 3 8.7 4 11.1 2 5.2 7 18.0 16 11.0
Mean SD Mean SD/Range Mean SD/Range Mean SD/Range Mean SD
Age 32.9 12.0 30.1 11.9 35.8 12.8 29.1 11.5 31.9 12.2
PANSS Total 76.8 13.5 77.2 14.2 76.2 14.6 74.4 12.8 76.1 13.7
PANSS Positive 20.2 4.6 21.7 4.6 21.0 4.2 20.4 4.6 20.8 4.5
PANSS Negative 21.7 8.0 18.7 7.9 19.8 7.2 19.0 7.0 19.8 7.5
PANSS General 34.8 6.5 36.9 7.8 35.3 7.3 35.0 6.7 35.5 7.1
CDSS 7.2 5.8 7.0 4.5 7.1 4.6 7.6 6.0 7.2 5.2
GAF-F 31.4 5.3 29.3 5.6 30.6 7.3 29.9 6.7 30.3 6.3
CGI 5.3 0.6 5.3 0.7 5.3 0.6 5.1 0.5 5.3 0.6
Notes: N= number of patients; SD = standard deviation; Antipsychotic naïve = No lifetime exposure to antipsychotic drugs before index admission; First admission =
Index admission was the first admission to a mental hospital; Misuse =Misuse or dependence according to Drake et al. [15]; Schz and rel. = Schizophrenia and related
disorders: Schizophrenia, schizoaffective disorder, acute polymorphic psychotic disorder with symptoms of schizophrenia, acute schizophrenia-like psychotic disorder,
delusional disorder; Acute = Acute psychosis other than those categorized under Schz and rel.; Affective = Affective psychosis; Rest =Miscellaneous psychotic disorders.
All diagnoses are according to ICD-10; PANSS = the Positive and Negative Syndrome Scale; CDSS = the Calgary Depression Scale for Schizophrenia; GAF-F = the Global
Assessment of Functioning, Split Version, Functions scale; CGI = the Clinical Global Impression, Severity of Illness Scale.
1 Patients with missing diagnoses are not included in the list.
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risperidone in reducing the hallucination score, with
olanzapine in an intermediate position, when the patients
were followed for up to 2 years. The finding is somewhat
unexpected as olanzapine and risperidone generally are
found to be slightly superior to some of the other SGAs
in recent meta-analyses of overall antipsychotic efficacy
[21,22]. The samples of most other randomized controlled
antipsychotic drug trials are however highly selected [23].
Our sample is more heterogeneous as reflected by the
diagnostic diversity and relatively low mean PANSS scores
with substantial inter-individual variation, which may ex-
plain the apparent discrepancy of the findings between
our study and others. For comparison, Sommer et al. [24]
recently published outcomes for hallucinations from theEUFEST study comparing the effectiveness of haloperidol,
olanzapine, amisulpride, quetiapine, and ziprasidone in pa-
tients with first-episode schizophrenia. In their total sample
of 498 patients, 73% had scores of at least 3 on the PANSS
hallucinatory behavior item, which is a comparable propor-
tion to the 68% in our study. The EUFEST subgroup with a
score of at least 3 on the PANSS hallucinations item had a
mean PANSS hallucinations score reduction from 4.4 to
2.5 during the first four weeks of treatment, and a further
reduction to 1.5 after 6 months [24]. Only 8% had halluci-
nations after 12 months. The corresponding reduction in
our study from baseline to maximally 6 weeks was from
3.6 to 2.0 points. One might expect that symptom reduc-
tion would be slower in our more heterogeneous sample as
response to antipsychotics is generally best in first-episode
days
PA
N
SS
 
ha
llu
ci
n
a
tio
n
s 
ite
m
0 100 200 300
1
2
3
4
5
6
7 Risperidone
Olanzapine
Quetiapine
Ziprasidone
Figure 3 Reduction of the mean hallucinations score. Linear slopes for the randomization groups generated based on linear mixed-effects
models for the PANSS hallucinatory behavior item. The curves are confined to the first 300 days because the major bulk of data is obtained
before 300 days. PANSS = the Positive and Negative Syndrome Scale.
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symptoms with each relapse [25,26]. At least in the acute
phase, no apparent differences in overall reduction of hal-
lucinations were evident between the EUFEST sample [24]
and our sample. With regards to comparisons between the
different antipsychotic drugs, haloperidol had the least
steep reduction of hallucinations for the groups included
in the EUFEST sample, and the difference was largest com-
pared to olanzapine, although not statistically significant
after adjusting for multiple comparisons [24]. The trend
for superiority of olanzapine in the EUFEST sample is,
according to the previous discussion, as expected, whereas
the finding of superiority for ziprasidone and quetiapine in
our sample is more surprising. Based on visual inspection
of the steepness of the growth curves for the individual
drugs in the EUFEST, ziprasidone and quetiapine seem to
be in intermediate positions among the drugs with regards
to mean decrease in hallucination severity [24]. This dis-
crepancy in results may indicate that our findings regard-
ing ziprasidone and quetiapine should be interpreted with
caution until replicated. The inferiority of haloperidol in its
effect on hallucinations is intriguing in relation to our find-
ing of risperidone as having the least steep reduction
for the hallucination score. All currently available anti-
psychotic drugs antagonize dopaminergic transmission at
the dopamine type 2 (D2) receptor, while SGAs are charac-
terized by a lower affinity for the D2 receptor than the
first-generation drugs, combined with a relatively strongerserotonergic antagonism at the 5HT2A receptor [27,28].
Pharmacologically, risperidone is the SGA that resembles
haloperidol closest with regards to D2 receptor affinity,
both drugs being very potent D2 receptor antagonists
[29,30]. Antipsychotic drug D2 receptor occupancy of 65-
70% has been proposed as the optimal therapeutic window
for antipsychotic efficacy [31]. However, accumulating evi-
dence indicates a more complex interplay with the dopa-
minergic system and that additional mechanisms beyond
D2 antagonism are at work mediating the antipsychotic
drug effects. It was recently demonstrated in a meta-
analysis that D2 receptor occupancy accounts for less than
20% of the clinical response variance [32]. Both quetiapine
and the SGA prototype – clozapine – have low affinities
for the D2 receptor and do not reach receptor occupancies
corresponding to the therapeutic window at clinical doses
[31,32]. The inferiority of haloperidol and risperidone
found in the EUFEST sample and our sample, respectively,
could thus be interpreted as additional support that potent
D2 receptor antagonism is not the only mediator of anti-
hallucinatory drug effects. With regards to alternative bio-
logical substrates of drug effects, a striking feature is the
pharmacological heterogeneity of antipsychotics [30,33].
Moreover, there is emerging evidence from both clinical
and preclinical studies suggesting differential effects among
the antipsychotic drugs on non-dopaminergic, non-
serotonergic drug targets suggesting that differential drug
effectiveness is to be expected in clinical samples with
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differences for antipsychotics may also be attributed to
methodological issues, as pointed out by Leucht and col-
laborators [23]. An advantage of the present study is the
use of the pragmatic, randomized design, emphasizing
more representative samples and treatment settings than
in traditional RCTs of efficacy, among others [41]. A differ-
ent aspect is that the vast majority of studies report sum
scores. However, idiosyncratic symptom profiles from dif-
ferent sub-samples may level each other out in the data of
the collected sample. Another advantage of the present
study is the specific focus on hallucinations. To the best of
our knowledge, clinical antipsychotic drug trials very rarely
study drug effects on single psychotic symptoms, and the
current results should encourage an increase in more
symptom-based studies, which could be extended to other
domains, such as gene-screening studies. The present
study focuses exclusively on data obtained during the
period of actual use of the drugs studied, which should in-
crease confidence in the findings of differential effective-
ness. The results are further strengthened by the serum
level measurements which revealed serum drug levels
within the reference ranges for all the comparators.
Some limitations should be mentioned. The pragmatic
design allows for broader inclusion criteria and fewer ex-
clusion criteria than for traditional RCTs of efficacy, but
still only 30% of those assessed for eligibility were in-
cluded in the study. Although this proportion is at the
higher end compared to many antipsychotic drug trials,
which may include as little as 10% of the population
under investigation [23], there is a risk of selection bias.
The direction of the influence of any selection bias re-
lated to our results is hard to predict. Another concern is
the high attrition rate in our study. Attrition is a major
problem in all antipsychotic drug studies and can exceed
40% in studies of only 4 to 10 weeks’ duration [23]. Total
attrition was, however, not related to any baseline clinical
or demographical characteristics and there were no differ-
ences among the randomization groups with regards to
mean duration of treatment. The randomization was open
to both the attending clinicians and the patients in order to
mimic usual clinical practice, but this could theoretically
have introduced bias if there were systematic utilization
differences among the drugs before the start of the study
and some of the SGAs under investigation were associated
with more prior experience than the others or were more
popular among the clinicians or patients. The direction of
such theoretical bias is hard to predict, as both negative
and positive prior experiences could influence the attitude
towards the SGAs under investigation. There were no sub-
stantial differences between the randomization groups with
regards to the agents used in the 12 months prior to inclu-
sion or in the proportion who accepted the first SGA on
the list. About half the sample had life-time exposure toantipsychotic drugs at study inclusion but noncompliance
is a common problem in this patient group and a frequent
cause of relapse [42], and most likely only a minority had
used antipsychotic drugs according to their prescriptions
in the last period of time before admittance. Serum drug
levels were not measured at admittance, so the exact fig-
ures cannot be verified. The secondary analyses based on
the actually chosen drugs failed to find statistically signifi-
cant differences among the groups.
Our primary analyses were, however, intention-to-treat
analyses based on the randomization groups. The second-
ary analyses do not take advantage of the randomization
and are accordingly vulnerable to confounding factors
which could have biased the results. There were indeed
statistically significant differences among the first-choice
groups on the PANSS positive subscale score.
Conclusions
Despite the limitations, the study suggests that differential
anti-hallucinatory effectiveness may exist between risperi-
done, olanzapine, quetiapine, and ziprasidone, but our
study results needs replication before any recommenda-
tions for specific drugs for hallucinating patients can be
made. The biological substrates mediating any potential
differential drug effects on hallucinations remain largely
unknown, but future studies with translational designs
should address this important issue to pave the way for a
more targeted pharmacotherapy of psychosis.
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